The Samueli Institute is submitting a clinical protocol to the FDA to continue use of the T/Tn Antigen Vaccine

 in the secondary prevention of breast cancer reoccurrence or progression in approximately fifty (50) women

 with breast cancer.

 

The Institute is seeking Proposals from GLP- or GMP-compliant biotechnological contractors to manufacturer

this vaccine. 

 

Letters of Intent are due: August 14, 2006
 

Full Proposal will be due: August 28, 2006. 
 

A complete description of this project is located: Manufacturing T/Tn based BreastCancer Vaccine